PRTA Stock Analysis: Buy, Sell, or Hold?
PRTA - Prothena Corporation plc Ordinary Shares
$8.88
0.06 (0.74%)
▲
5d:
-10.71%
30d:
-7.07%
90d:
-15.31%
WAIT
LOW Confidence
Last Updated: January 30, 2026
Earnings: Feb 19, 2026
16d
Get Alerted When PRTA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: PRTA is down 10.7% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: PRTA is down 10.7% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$13.51
Based on 7.0% avg growth
INTRINSIC VALUE TODAY
$8.39
Trading above fair value
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 18.3x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: PRTA is currently trading at $8.88, which is considered oversold relative to its 30-day fair value range of $8.95 to $9.70. The stock's valuation (Forward PE: 16.7) is in line with its historical norms (18.3). Remarkably, the market is currently pricing in an annual earnings decline of 3.0% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, PRTA is in a strong uptrend. The price is currently testing key support at $8.65. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: PRTA has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $20.33 (+130.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, PRTA is in a strong uptrend. The price is currently testing key support at $8.65. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: PRTA has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $20.33 (+130.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Fair Price Range
$8.95 -
$9.70
Company Quality Score
50/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
65.4%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Options cheap (IV 0th percentile)
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 130.8% below Wall St target ($20.33)
- WARNING: Recommendation downgraded due to -10.7% 5-day decline - wait for stabilization
Fair Price Analysis
30-Day Fair Range
$8.95 -
$9.70
Current vs Fair Value
OVERSOLD
Expected Move (7 Days)
±$0.64
(7.3%)
Support & Resistance Levels
Support Level
$8.65
Resistance Level
$10.53
Current Trend
Strong Uptrend
Fundamental Context
Forward P/E (Next Year Est.)
16.73
Wall Street Target
$20.33
(+130.8%)
Revenue Growth (YoY)
149.0%
Valuation Discount vs History
-3.0% cheaper
PE vs Historical
16.7 vs 18.3
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-3.0%
(market-implied from PE analysis)
1-Year Target
$8.55
(-3%)
2-Year Target
$8.29
(-6%)
3-Year Target
$8.04
(-9%)
3-Yr Target (if PE normalizes)
(PE: 17→18)
$8.80
(0%)
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 16.7 to 18.3
Stabilization Target:
$9.64
(+9.4%)
PE Expansion Potential:
+9.4%
Last updated: February 02, 2026 10:17 AM ET
Data refreshes hourly during market hours. Next update: 11:17 AM
Data refreshes hourly during market hours. Next update: 11:17 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is PRTA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$91 | 59 HOLD |
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$24 | 60 HOLD |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$85 | 57 HOLD |
|
KYMR
Kymera Therapeutics Inc |
STRONG BUY
20 analysts |
$117 | 59 HOLD |
|
BNTX
BioNTech SE |
STRONG BUY
21 analysts |
$140 | 59 HOLD |
